Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) Stock
Key stats
- Market cap
- $7.78B
- Price / Earnings ratio
- -39.8x
- EPS (TTM)
- -$2.90
- Volume
- Loading
- 52-week high
- $122.20
- 52-week low
- $74.50
Source: third-party data provider, as of November 13, 2026
Compare with RYTM
Recent news

RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report
RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report
RYTM

Rhythm Pharmaceuticals Q3 Earnings Call Highlights
Rhythm Pharmaceuticals Q3 Earnings Call Highlights
RYTM

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates
RYTM

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
RYTM
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 65.45
- MACD 12/26/9
- 4.82
- EMA 9 of MACD
- 2.00
- MACD histogram
- 2.82
- SMA 50
- $96.59
- Price above SMA 50
- EMA 50
- $98.55
- Price above EMA 50
- SMA 200
- $97.15
- Price above SMA 200
- EMA 200
- $98.36
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report
RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report
RYTM

Rhythm Pharmaceuticals Q3 Earnings Call Highlights
Rhythm Pharmaceuticals Q3 Earnings Call Highlights
RYTM

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates
RYTM

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
RYTM

Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know
Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know
RYTM

Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
RYTM

Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts
RYTM

Rhythm Pharmaceuticals Q2 Earnings Call Highlights
Rhythm Pharmaceuticals Q2 Earnings Call Highlights
RYTM

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
RYTM

Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
RYTM
News tone: automated (AI) classification of the article's content, not a price prediction.
About Rhythm Pharmaceuticals, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. David P. Meeker M.D. | Chairman, President & CEO | 1954 |
| Mr. Hunter C. Smith M.B.A. | CFO & Treasurer | 1969 |
| Dr. Alastair Garfield Ph.D. | Chief Scientific Officer | 1980 |
| Mr. Yann Mazabraud | Executive VP & Head of International | 1973 |
| Ms. Jennifer Lee | Executive VP & Head of North America | 1975 |
| Mr. Christopher P. German | Corporate Controller & Principal Accounting Officer | 1972 |
| Mr. Joseph Shulman | Chief Technical Officer | 1975 |
| Mr. David Connolly | Head of Investor Relations & Corporate Communications | — |
| Mr. Jim Flaherty | Senior VP & General Counsel | — |
| Ms. Sarah Ryan | Vice President of Sales & Marketing | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 65.45
- MACD 12/26/9
- 4.82
- EMA 9 of MACD
- 2.00
- MACD histogram
- 2.82
- SMA 50
- $96.59
- Price above SMA 50
- EMA 50
- $98.55
- Price above EMA 50
- SMA 200
- $97.15
- Price above SMA 200
- EMA 200
- $98.36
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $114.00
- Average
- $139.71
- High
- $166.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -32.4 | +15.8 | ||||||||||
| 2022 | -30.6 | -0.5 | +35.7 | -46.9 | -45.4 | +23.1 | +193.0 | +81.5 | -3.3 | +6.2 | +2.3 | +7.9 |
| 2023 | -4.5 | -11.1 | -31.0 | +8.4 | -17.6 | -4.0 | +10.6 | +14.3 | -17.5 | +4.6 | +39.3 | +36.0 |
| 2024 | -2.3 | -6.3 | -0.9 | -6.8 | -13.9 | +8.5 | +13.0 | +1.0 | +14.0 | -7.8 | +26.6 | -8.0 |
| 2025 | -1.1 | -7.6 | +1.1 | +30.4 | -3.9 | -0.7 | +30.2 | +16.8 | -3.1 | +13.7 | -4.1 | +1.9 |
| 2026 | -2.4 | -14.9 | -8.4 | -7.7 | +8.0 | +26.4 | -10.1 | +3.3 | -9.1 | -0.9 | +20.0 |



